Literature DB >> 6354430

The tumor phenotype and the human gene map.

N K Honey, T B Shows.   

Abstract

The tumor phenotype is associated with the rearrangement of genetic information and the altered expression of many gene products. In this review, genes associated with the tumor phenotype have been arranged on the human gene map and indicate the extent to which the tumor phenotype involves the human genome. Nonrandom chromosomal aberrations that are frequently observed in tumors are presented. Altered metabolic demands of the tumor cell are reflected in altered gene expressions of a wide range of enzymes and other proteins, and these changed enzyme patterns are described. The study of oncogenes increasingly suggests that they may be significant in certain cancers, and the assignment of these genes has been tabulated. The biochemical and metabolic changes observed in tumors are complex; studying the patterns and interactions of these changes will aid our genetic understanding of the origins and development of tumors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354430      PMCID: PMC7119902          DOI: 10.1016/0165-4608(83)90058-4

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  77 in total

Review 1.  Enzymology of cancer cells (second of two parts).

Authors:  G Weber
Journal:  N Engl J Med       Date:  1977-03-10       Impact factor: 91.245

Review 2.  Developmental gene expression in cancer.

Authors:  K H Ibsen; W H Fishman
Journal:  Biochim Biophys Acta       Date:  1979-08-10

Review 3.  A review of isozymes in cancer.

Authors:  W E Criss
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

4.  Purification, properties, and immunotitration of hepatoma glutamine phosphoribosylpyrophosphate amidotransferase (amidophosphoribosyltransferase, EC 2.4.2.14).

Authors:  M Tsuda; N Katunuma; H P Morris; G Weber
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

5.  Mechanism of activation of a human oncogene.

Authors:  C J Tabin; S M Bradley; C I Bargmann; R A Weinberg; A G Papageorge; E M Scolnick; R Dhar; D R Lowy; E H Chang
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

6.  [Structural and numerical chromosome abnormalities in human malignant melanoma cell lines (author's transl)].

Authors:  S Bertrand; E Lefthériotis; J F Doré
Journal:  C R Seances Acad Sci III       Date:  1982-03-15

7.  Translocation of immunoglobulin VH genes in Burkitt lymphoma.

Authors:  J Erikson; J Finan; P C Nowell; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

8.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.

Authors:  E P Reddy; R K Reynolds; E Santos; M Barbacid
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

9.  A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC).

Authors:  J Whang-Peng; P A Bunn; C S Kao-Shan; E C Lee; D N Carney; A Gazdar; J D Minna
Journal:  Cancer Genet Cytogenet       Date:  1982-06

10.  Activation of related transforming genes in mouse and human mammary carcinomas.

Authors:  M A Lane; A Sainten; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

View more
  3 in total

1.  Molecular dissection of mutations at the heterozygous thymidine kinase locus in mouse lymphoma cells.

Authors:  M L Applegate; M M Moore; C B Broder; A Burrell; G Juhn; K L Kasweck; P F Lin; A Wadhams; J C Hozier
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

2.  Heterogeneity of isozyme expression in tumor cells does not correlate with metastatic potential.

Authors:  S L Aukerman; M J Siciliano; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1986 Jul-Sep       Impact factor: 5.150

3.  Identification of a single chromosome in the normal human genome essential for suppression of hamster cell transformation.

Authors:  A Stoler; N Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.